Navigation Links
Swine flu experts gather at New York Academy of Sciences May 28
Date:5/27/2009

The very latest information on the 2009 swine influenza (H1N1) outbreak is the subject of a landmark afternoon symposium hosted by the New York Academy of Sciences on Thursday, May 28. Speakers will discuss the new recombinant virus, epidemiology, treatment, vaccine development and the public health implications of a worldwide pandemic.

Reservations are required to attend the conference, held from 12:30 p.m. to 5:30 p.m., at academy offices, 7 World Trade Center, 40th floor, 250 Greenwich St. at Barclay St. A reception will follow.

Two microbiologists/immunologists from New York Medical College are leading the symposium, which will focus on understanding the pathogenicity and transmission of the viruses to develop improved methods of prevention and control. Keynote speaker Edwin D. Kilbourne, M.D., emeritus professor, developed the first genetically engineered vaccine of any kind more than 30 years ago. He is an internationally recognized research scientist who has made significant contributions to the study and prevention of influenza and other viral diseases.

Doris Bucher, Ph.D., associate professor, whose laboratory in Valhalla is one of just three worldwide that reproduces "seed" viruses for the influenza vaccine, which begins the process of producing some 450 million doses of a new vaccine each year. Dr. Bucher is the symposium organizer.

Speakers include Michael Shaw, CDC Influenza Division; Dominick A. Iacuzio, Hoffman-La Roche, Inc.; Kanta Subbarao, NIH Laboratory of Infectious Diseases; John Treanor, University of Rochester School of Medicine and Dentistry; Philip R. Dormitzer, Novartis Vaccines; Scott Harper, New York City Department of Health and Mental Hygiene; and James Matthews, Sanofi Pasteur, moderator.


'/>"/>

Contact: Donna E. Moriarty, M.P.H.
donna_moriarty@nymc.edu
914-439-5989
New York Medical College
Source:Eurekalert

Page: 1

Related biology news :

1. Contrast agent trials in swine
2. Improving swine waste fertilizer
3. Study finds MRSA in Midwestern swine, workers
4. Avian flu research sheds light on swine flu outbreak
5. K-State researcher finds 1918 flu resulted in current lineage of H1N1 swine influenza viruses
6. Swine flu genes dissimilar to past pandemics
7. HudsonAlpha investigator develops rapid response swine flu test
8. Swine flu: What does it do to pigs?
9. Leading experts cite poor health and nutrition as major barrier to education in developing world
10. Improving science, technology in Africa is aim as G-8, African, UN experts convene in Berlin
11. Less Arctic ice means higher risks, experts warn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)...   Acuant , a leading provider of data ... to new and core technologies building upon the acquisition ... and desktop Acuant FRM TM facial recognition and ... time manual review of identity documents by accredited professionals. ... and most accurate capture software to streamline workflows by ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
Breaking Biology Technology: